Compare GE Aerospace (GE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Merck & Co., Inc. — how do they compare? GE Aerospace trades at $307 (market cap $317.10B), while Merck & Co., Inc. trades at $142.03 (market cap $351.28B). The key difference: GE Aerospace and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Merck & Co., Inc. for 98 Days on average.
| GE | MRK | |
|---|---|---|
Market Cap | $317.10B | $351.28B |
Volume | 6,320,106 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $381.22 | $156.43 |
52-Week Low | $273.25 | $82.49 |
Typical Hold Time | 111 Days | 98 Days |
Enterprise Value | $326.91B | $398.04B |
Dividend Yield | 0.62% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $305.62, down 1.22% amid broader market weakness, with technical indicators showing bearish momentum below key moving averages. Fundamentally, the company demonstrates strong profitability with 17.72% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights the strategic $12 billion CPP acquisition to address supply chain constraints while maintaining robust shareholder returns through dividends and buybacks.
The outlook remains constructive given strong defense demand and operational execution, but high valuation and acquisition integration risks warrant caution. Analyst consensus is strongly bullish with a $409.60 price target representing 34% upside, though near-term technical pressure may persist until the Q3 earnings report provides clearer direction.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
